| 1 |
35631351 | Obeticholic Acid Reduces Kidney Matrix Metalloproteinase Activation Following Partial Hepatic Ischemia/Reperfusion Injury in Rats. | 2022 Apr 24 |
2 |
| 2 |
33578971 | Unaltered Liver Regeneration in Post-Cholestatic Rats Treated with the FXR Agonist Obeticholic Acid. | 2021 Feb 10 |
2 |
| 3 |
32371093 | Opposite effects of the FXR agonist obeticholic acid on Mafg and Nrf2 mediate the development of acute liver injury in rodent models of cholestasis. | 2020 Sep |
1 |
| 4 |
32725149 | Obeticholic acid ameliorates hepatorenal syndrome in ascitic cirrhotic rats by down-regulating the renal 8-iso-PGF2α-activated COX-TXA2 pathway. | 2020 Aug 14 |
4 |
| 5 |
30674010 | Therapeutic effects of the selective farnesoid X receptor agonist obeticholic acid in a monocrotaline-induced pulmonary hypertension rat model. | 2019 Aug |
5 |
| 6 |
30409980 | FXR agonist obeticholic acid induces liver growth but exacerbates biliary injury in rats with obstructive cholestasis. | 2018 Nov 8 |
1 |
| 7 |
27425465 | Cardiopulmonary protective effects of the selective FXR agonist obeticholic acid in the rat model of monocrotaline-induced pulmonary hypertension. | 2017 Jan |
3 |
| 8 |
28060943 | Farnesoid X Receptor Activation Attenuates Intestinal Ischemia Reperfusion Injury in Rats. | 2017 |
2 |
| 9 |
28115235 | Anti-fibrotic effects of chronic treatment with the selective FXR agonist obeticholic acid in the bleomycin-induced rat model of pulmonary fibrosis. | 2017 Apr |
3 |
| 10 |
28130067 | Farnesoid X Receptor Activation Promotes Hepatic Amino Acid Catabolism and Ammonium Clearance in Mice. | 2017 May |
1 |
| 11 |
27255380 | Pyrazinamide Induced Rat Cholestatic Liver Injury through Inhibition of FXR Regulatory Effect on Bile Acid Synthesis and Transport. | 2016 Aug |
2 |
| 12 |
27634375 | FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis. | 2016 Sep 16 |
1 |
| 13 |
25152204 | Hepatic dimethylarginine-dimethylaminohydrolase1 is reduced in cirrhosis and is a target for therapy in portal hypertension. | 2015 Feb |
1 |
| 14 |
25592258 | The FXR agonist obeticholic acid prevents gut barrier dysfunction and bacterial translocation in cholestatic rats. | 2015 Feb |
1 |
| 15 |
19783811 | FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats. | 2010 Apr |
3 |
| 16 |
19027009 | ATP8B1 deficiency disrupts the bile canalicular membrane bilayer structure in hepatocytes, but FXR expression and activity are maintained. | 2009 Mar |
1 |
| 17 |
15644430 | Protective effects of 6-ethyl chenodeoxycholic acid, a farnesoid X receptor ligand, in estrogen-induced cholestasis. | 2005 May |
3 |
| 18 |
15980055 | Cross-talk between farnesoid-X-receptor (FXR) and peroxisome proliferator-activated receptor gamma contributes to the antifibrotic activity of FXR ligands in rodent models of liver cirrhosis. | 2005 Oct |
2 |
| 19 |
16178789 | Role of FXR in regulating bile acid homeostasis and relevance for human diseases. | 2005 Sep |
1 |
| 20 |
15521018 | The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis. | 2004 Nov |
2 |
| 21 |
12166927 | 6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. | 2002 Aug 15 |
4 |